Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

doi:10.1016/j.lungcan.2020.09.018

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2020

Garcia-Campelo Rosario, Arrieta Oscar, Massuti Bartomeu, Rodriguez-Abreu Delvys, Granados Ana Laura Ortega, Majem Margarita, Vicente David, Lianes Pilar, Bosch-Barrera Joaquim, Insa Amelia, Dómine Manuel, Reguart Noemí, Guirado María, Sala María Ángeles, Vázquez-Estevez Sergio, Caro Reyes Bernabé, Drozdowskyj Ana, Verdú Ana, Karachaliou Niki, Molina-Vila Miguel Angel, Rosell Rafael

Abstract excerpt

OBJECTIVES: Progression-free survival (PFS) and response rate to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung cancer (NSCLC) driven byEGFR mutations, suggesting that other genetic alterations may influence oncogene addiction. Low BRCA1 mRNA levels correlate with longer PFS in erlotinib-treated EGFR-mutant NSCLC patients. Since the poly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Gefitinib

Share to Mexico

Share to Phthalazines

Share to Piperazines

Share to Quinazolines

Share to Spain

Source

Open in PubMed

Identifiers

PMID: 33070053
DOI: 10.1016/j.lungcan.2020.09.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).PMID 33070053Read ↗

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Semantic proximity Read ↗

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM Mutation: A Case Report.Semantic proximity Read ↗

The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.Semantic proximity Read ↗

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.Semantic proximity Read ↗

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity Read ↗

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerSemantic proximity Read ↗

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.Semantic proximity Read ↗

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read ↗

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity Read ↗

Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.Semantic proximity Read ↗

Olaparib shows promise in multiple tumor types.Semantic proximity Read ↗

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.